Year: 2024
Type: editorial
Abstract: High Resolution Image Download MS PowerPoint Slide The strategy of classical chiral switches of drugs is still alive, contrary to a 2024 Journal of Medicinal Chemistry Perspective on approved chiral drugs claiming its death. Surveys of approved chiral-switch and racemic drugs should be based on reports of global regulatory authorities, not just FDA and EMA, which revealed overlooked chiral switches and racemates. The approved antihypertensive racemate nebivolol indicates the synergy between its enantiomers, highlighting the advocacy of developing racemic drugs.
Source: ACS Medicinal Chemistry Letters
Authors: Israel Agranat, Ilaria D’Acquarica
Institutions: Hebrew University of Jerusalem, Sapienza University of Rome
Language: English
Subfield: Spectroscopy
Field: Chemistry
Domain: Physical Sciences
Open Access status: green
OpenAlex ID: W4403295879